KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Investing Activities (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Cash from Investing Activities for 6 consecutive years, with $75.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities rose 110.45% year-over-year to $75.1 million, compared with a TTM value of $87.8 million through Dec 2025, down 27.72%, and an annual FY2025 reading of $87.8 million, down 27.72% over the prior year.
  • Cash from Investing Activities was $75.1 million for Q4 2025 at AbCellera Biologics, up from $36.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $75.1 million in Q4 2025 and bottomed at -$282.0 million in Q3 2022.
  • Average Cash from Investing Activities over 5 years is -$34.8 million, with a median of -$16.5 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities plummeted 6840.18% in 2021, then skyrocketed 886.7% in 2025.
  • Year by year, Cash from Investing Activities stood at -$1.1 million in 2021, then crashed by 1385.03% to -$17.1 million in 2022, then plummeted by 42.55% to -$24.3 million in 2023, then surged by 246.79% to $35.7 million in 2024, then soared by 110.45% to $75.1 million in 2025.
  • Business Quant data shows Cash from Investing Activities for ABCL at $75.1 million in Q4 2025, $36.5 million in Q3 2025, and -$31.8 million in Q2 2025.